Xenetic Biosciences (XBIO) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" XBIO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XBIO, but not buy additional shares or sell existing shares.
View XBIO analyst ratings or view top-rated stocks.

1 equities research analysts have issued 1 year price targets for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $40.00 to $40.00. On average, they predict the company's stock price to reach $40.00 in the next year. This suggests a possible upside of 716.3% from the stock's current price.
View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts.

Xenetic Biosciences' stock was trading at $2.8510 at the beginning of 2023. Since then, XBIO shares have increased by 71.9% and is now trading at $4.90.
View the best growth stocks for 2023 here.

Xenetic Biosciences saw a increase in short interest in September. As of September 15th, there was short interest totaling 16,400 shares, an increase of 127.8% from the August 31st total of 7,200 shares. Based on an average daily volume of 17,100 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.2% of the company's stock are short sold.
View Xenetic Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our XBIO earnings forecast.

Xenetic Biosciences Inc (NASDAQ:XBIO) announced its quarterly earnings results on Friday, August, 11th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.44. The business earned $0.65 million during the quarter, compared to analysts' expectations of $0.44 million. Xenetic Biosciences had a negative net margin of 194.39% and a negative trailing twelve-month return on equity of 31.72%.

Xenetic Biosciences shares reverse split on Monday, May 15th 2023. The 1-10 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XBIO stock can currently be purchased for approximately $4.90.

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $7.50 million and generates $1.71 million in revenue each year. The company earns $-6,550,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis.

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.